Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Marts 2019

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #558

    NHS will not directly fund it, it will be reimbursed out of the Cancer Drugs Fund (CDF), just like currently is the case with mono

    1 Reply Last reply
    0
    • P Offline
      P Offline
      peter12
      wrote on sidst redigeret af
      #559

      Genmab var shortet 4,04% 28 feb. Det har ligget på 3-4% det sidste år. Det er positioner over 0,2%

      1 Reply Last reply
      0
      • J Offline
        J Offline
        Joakim_Von_And
        wrote on sidst redigeret af
        #560

        Ja,, kunne der komme et bud , så de hurtigt ville i 0 ,, det ville glæde mig at de brændte nallerne lidt...

        1 Reply Last reply
        0
        • StockBullS Offline
          StockBullS Offline
          StockBull
          wrote on sidst redigeret af
          #561

          2.5 - 5% det sıdste aars tıd 🙂

          1 Reply Last reply
          0
          • StockBullS Offline
            StockBullS Offline
            StockBull
            wrote on sidst redigeret af
            #562

            1.5 aars tıd

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #563

              Så kender man Genmab igen - svag som i svag.

              1 Reply Last reply
              0
              • T Offline
                T Offline
                Tandfeen-2
                wrote on sidst redigeret af
                #564

                Desværre også på en grøn dag

                1 Reply Last reply
                0
                • Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktør
                  wrote on sidst redigeret af
                  #565

                  Genmab og Novo følges ad med minus 0,22 og 0,26% i dag. Værre er det ikke.

                  1 Reply Last reply
                  0
                  • concilladoC Offline
                    concilladoC Offline
                    concillado
                    wrote on sidst redigeret af
                    #566

                    GEN's kurs klargør blot at lægge sig favorabelt til os trofaste investorer, så vi kan full value, når vi skal brænde vores overskydende skat af lige om lidt! 😉

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #567

                      New trial : Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) https://clinicaltrials.gov/ct2/show/NCT03871829

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #568

                        and it looks like they will give this one another try https://clinicaltrials.gov/ct2/history/NCT03346135?A=5&B=6&C=merged

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #569

                          and the Tisotumab Vedotin safety study published the results
                          https://clinicaltrials.gov/ct2/history/NCT02552121?A=10&B=11&C=merged

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #570

                            well , at least NICE itself also calls daratumumab a “potentially game-changing” treatment https://twitter.com/NICEcomms/status/1105468491388338176

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #571

                              Note the inverted commas 😉

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #572

                                😉

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  peter12
                                  wrote on sidst redigeret af
                                  #573

                                  They don't believe it has proved to be cost effective yet but : "The patient experts stated that the psychological benefit of delaying a second relapse had not been captured in the quality-of-life measure in the trial. The committee agreed that this had not been captured in the model."

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #574

                                    Janssen Submits Application to U.S. FDA … Application supported by the Phase 3 MAIA study being reviewed under the FDA Real-Time Oncology Review pilot program
                                    https://www.prnewswire.com/news-releases/janssen-submits-application-to-us-fda-seeking-approval-of-darzalex-daratumumab-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-ineligible-300811239.html

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #575

                                      so roughly 4 more weeks from now?

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #576

                                        Nice - lets hope so

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #577

                                          🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger